netbook
desktop
mobile
tablet-landscape
tablet
phone-landscape
phone
Research to Prevent Blindness

Researchers Identify Treatment Target for Blinding Retinal Diseases

New research published today in Cell Reports identifies a potential treatment target for blinding diseases such as retinitis pigmentosa and advanced dry age-related macular degeneration. In the study, researchers at Washington University in St. Louis School of Medicine (supported in part by an unrestricted Research to Prevent Blindness grant to the Department of Ophthalmology) explored how the retina's photoreceptors—the rods and cones responsible for detecting light, color, contrast, and sharpness—are damaged over the course of these diseases.

"We believe we have uncovered a unifying pathway involved in inflicting severe damage to and even causing the death of rods and cones," said Jonathan B. Lin, an MD/PhD student and co-first author with Shunsuke Kubota, MD, PhD. "These findings should help us develop treatments for retinal disorders, regardless of what's causing them."

Lin works in the laboratory of senior investigator Rajendra S. Apte, MD, PhD, the Paul A. Cibis Distinguished Professor of Ophthalmology and Visual Sciences, who is a recipient of an RPB Physician-Scientist Award and also recently published key findings on the Zika virus. In a series of experiments in mice and retinal cells, the researchers identified a key molecule —NAD — in the cascade that leads to the death of the retina's rods and cones.

MD/PhD student Jonathan Lin (left) and Rajendra S. Apte, MD, PhD, of Washington University School of Medicine in St. Louis. Photo credit: Robert Boston / Washington University

Lin, Apte and colleagues found that defects in the same NAD pathway appeared to be involved in several different diseases of the retina. When they treated damaged photoreceptor cells in mice with a second molecule called NMN — a precursor molecule that boosts levels of NAD — the cells' degeneration ceased and vision was restored.

"This is exciting because we may have found a reason why these highly metabolically active cells are susceptible to damage and death when the NAD pathway does not function optimally," said Apte, also a professor of developmental biology and neuroscience and of medicine.

The pathway offers a promising target for therapies for multiple retinal diseases, including retinitis pigmentosa, one of the leading causes of blindness that impairs vision over many years and for which there is currently no cure.

Learn more about the study from the Washington University in St. Louis School of Medicine press release and podcast

Related News: Top Story

RPB AWARDS $5.4 MILLION IN GRANTS

The latest grant cycle supports eye research related to a variety of diseases and conditions.

Read More

 

Natural Compound Reduces Signs of Aging, Including Eye Dryness

RPB-supported vision researchers at Washington University School of Medicine in St. Louis have contributed key data to a new study that identifies a natural compound that slows typical signs of aging in mice.

Read More

 

Emerging Vision Scientists Visit Capitol Hill

Twenty-two emerging vision scientists conducted Capitol Hill visits with NAEVR and RPB to champion federal funding for critical vision research.

Read More

 

New Report Aims to Make Eye Health a Public Health Priority

The National Academies of Sciences, Engineering, and Medicine issues nine concrete recommendations for improving eye and vision health and increasing health equity.

Read More

 

Zika Virus Found in Tears

Researchers publish critical findings from Zika mouse model, raising the possibility of new avenues of transmission, as well as confirming the virus’ ability to induce cell death in eyes.

Read More

 

RPB Announces First Low Vision Research Awardees

Research initiative to address urgent needs in understanding and treating low vision.

Read More

 

Subscribe

Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.